Literature DB >> 19762488

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE).

Masahiro Hiasa1, Masahiro Abe, Ayako Nakano, Asuka Oda, Hiroe Amou, Shinsuke Kido, Kyoko Takeuchi, Kumiko Kagawa, Kenichiro Yata, Toshihiro Hashimoto, Shuji Ozaki, Kenzo Asaoka, Eiji Tanaka, Keiji Moriyama, Toshio Matsumoto.   

Abstract

Monocytes give rise to macrophages, osteoclasts (OCs), and dendritic cells (DCs). Macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kappaB (RANK) ligand induce OC differentiation from monocytes, whereas granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) trigger monocytic differentiation into DCs. However, regulatory mechanisms for the polarization of monocytic differentiation are still unclear. The present study was undertaken to clarify the mechanism of triggering the deflection of OC and DC differentiation from monocytes. GM-CSF and IL-4 abolished monocytic differentiation into OCs while inducing DC differentiation even in the presence of M-CSF and RANK ligand. GM-CSF and IL-4 in combination potently up-regulate tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) and activity in monocytes, causing ectodomain shedding of M-CSF receptor, resulting in the disruption of its phosphorylation by M-CSF as well as the induction of osteoclastogenesis from monocytes by M-CSF and RANK ligand. Interestingly, TACE inhibition robustly causes the resumption of the surface expression of M-CSF receptor on monocytes, facilitating M-CSF-mediated phosphorylation of M-CSF receptor and macrophage/OC differentiation while impairing GM-CSF- and IL-4-mediated DC differentiation from monocytes. These results reveal a novel proteolytic regulation of M-CSF receptor expression in monocytes to control M-CSF signaling and monocytic differentiation into macrophage/OC-lineage cells or DCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762488     DOI: 10.1182/blood-2009-04-215020

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

Review 2.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

3.  Antibody Cross-Linking of CD14 Activates MerTK and Promotes Human Macrophage Clearance of Apoptotic Neutrophils: the Dual Role of CD14 at the Crossroads Between M1 and M2c Polarization.

Authors:  Gaetano Zizzo; Philip L Cohen
Journal:  Inflammation       Date:  2018-12       Impact factor: 4.092

4.  Deficient arginase II expression without alteration in arginase I expression attenuated experimental autoimmune encephalomyelitis in mice.

Authors:  Mariam Choudry; Xiaolei Tang; Tiffany Santorian; Samiksha Wasnik; Jidong Xiao; Weirong Xing; Kin-Hing William Lau; Subburaman Mohan; David J Baylink; Xuezhong Qin
Journal:  Immunology       Date:  2018-04-16       Impact factor: 7.397

5.  The relative timing of exposure to phagocytosable particulates and to osteoclastogenic cytokines is critically important in the determination of myeloid cell fate.

Authors:  Douglas E James; Bryan J Nestor; Thomas P Sculco; Lionel B Ivashkiv; F Patrick Ross; Steven R Goldring; P Edward Purdue
Journal:  J Immunol       Date:  2010-06-11       Impact factor: 5.422

6.  Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.

Authors:  Ayako Nakano; Hirokazu Miki; Shingen Nakamura; Takeshi Harada; Asuka Oda; Hiroe Amou; Shiro Fujii; Kumiko Kagawa; Kyoko Takeuchi; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 7.  Targeting mucosal immunity in the battle to develop a mastitis vaccine.

Authors:  Mini Bharathan; Isis K Mullarky
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-10-04       Impact factor: 2.673

8.  Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.

Authors:  M Hiasa; J Teramachi; A Oda; R Amachi; T Harada; S Nakamura; H Miki; S Fujii; K Kagawa; K Watanabe; I Endo; Y Kuroda; T Yoneda; D Tsuji; M Nakao; E Tanaka; K Hamada; S Sano; K Itoh; T Matsumoto; M Abe
Journal:  Leukemia       Date:  2014-05-02       Impact factor: 11.528

9.  Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.

Authors:  Matthew R Farren; Louise M Carlson; Colleen S Netherby; Inna Lindner; Pui-Kai Li; Dmitry I Gabrilovich; Scott I Abrams; Kelvin P Lee
Journal:  Sci Signal       Date:  2014-02-18       Impact factor: 8.192

10.  Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.

Authors:  Shingen Nakamura; Hirokazu Miki; Shinsuke Kido; Ayako Nakano; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Keiichiro Watanabe; Takeshi Harada; Shiro Fujii; Kyoko Takeuchi; Kumiko Kagawa; Shuji Ozaki; Toshio Matsumoto; Masahiro Abe
Journal:  Int J Hematol       Date:  2013-05-25       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.